Radiotherapy & Oncology
Volume 96, Issue 3 , Pages 317-324 , September 2010

Physical radiotherapy treatment planning based on functional PET/CT data

  • Daniela Thorwarth

      Affiliations

    • Section for Biomedical Physics, University Hospital for Radiation Oncology, Tübingen, Germany
    • Corresponding Author InformationCorresponding author. Address: Section for Biomedical Physics, University Hospital for Radiation Oncology, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.
    • ,
  • Xavier Geets

      Affiliations

    • Department of Radiation Oncology, St-Luc University Hospital, Brussels, Belgium
    • ,
  • Marta Paiusco

      Affiliations

    • Medical Physics Department, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

Received 9 July 2010 ,Revised 12 July 2010 ,Accepted 13 July 2010.

References 

  1. Keall P. 4-Dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol. 2004;14:81–90
  2. Boellard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200
  3. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol. 2009;91:85–94
  4. Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol. 2009;54:R1–R25[review]
  5. Ford EC, Herman J, Yorke E, Wahl RL. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med. 2009;50:1655–1665[review]
  6. Zaidi H, Vees H, Wissmeyer M. Molecular PET/CT image-guided radiotherapy treatment planning. Acad Radiol. 2009;16:1108–1133[review]
  7. Yu W, Fu X-L, Zhang Y-J, et al. GTV spatial conformity between different delineation methods by 18FDG PET/CT and pathology in esophageal cancer. Radiother Oncol. 2009;93:441–446
  8. Muijs CT, Schreurs LM, Busz DM, et al. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiother Oncol. 2009;93:447–453
  9. de Figueiredo BH, Barret O, Demeaux H, et al. Comparison between CT- and FDG-PET-defined target volumes for radiotherapy planning in head-and-neck cancers. Radiother Oncol. 2009;93:479–482
  10. Wang H, Vees H, Miralbell R, et al. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol. 2009;93:220–225
  11. Geets X, Tomsej M, Lee JA, et al. Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumours: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol. 2007;85:105–115
  12. Nestle U, Walter K, Achmidt S, et al. 18F deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atalectasis. Int J Radiat Oncol Biol Phys. 1999;44:593–597
  13. Geets X, Daisne JF, Tomsej M, et al. Impact of the type of imaging modality on target volume delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre and per-treatment studies. Radioter Oncol. 2006;78:291–297
  14. Douglas JG, Stelzer KJ, Mankoff DA, et al. [18-F] fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2006;64:886–891
  15. Grosu AL, Souvatzogluo M, Röper B, et al. Hypoxia imaging with FAZA-PET and theoretical consideration with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:541–551
  16. Lee NY, Mechalakos J, Nemeh S, et al. Fluorine-18 labeled fluoromisonidazole positron emission and computed tomography guided intensity modulated radiotherapy for head and neck cancer; a feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2–13
  17. Rajendran JG, Hendrickson KRG, Spence AM, et al. Hypoxia imaging directed radiation treatment planning. Eur J Nucl Med Mol Imaging. 2006;33:S44–S53
  18. Seppälä J, Seppänen M, Arponen E, Lindholm P, Minn H. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol. 2009;93:234–240
  19. Pinkawa M, Attieh C, Piroth MD, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer–evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol. 2009;93:213–219
  20. Lin Z, Mechalakos J, Nehmeh S, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on [18F]-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70:1219–1228
  21. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance. Cu-ATSM guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171–1182
  22. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-l-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009;30:908–917
  23. Schaefer A, Kremp S, Hellwig D, Rübe C, Kirsch CM, Nestle U. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging. 2008;35:1989–1999
  24. Esthappan J, Chaudhari S, Santanam L, et al. Prospective clinical trial of positron emission tomography/computed tomography image-guided intensity modulated radiation therapy for cervical carcinoma with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2008;72:1134–1139
  25. Schinagl DAX, Hoffmann AL, Vogel WV, et al. Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer?. Radiother Oncol. 2009;91:95–100
  26. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–560
  27. Vanderstraeten B, Duthoy W, De Gersem W, et al. [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity based intensity modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol. 2006;79:249–258
  28. Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol. 2003;48:N31–N35
  29. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112–117
  30. Petit SF, Aerts HJWL, van Loon JGM, et al. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): An exploratory clinical study. Radiother Oncol. 2009;91:393–398
  31. Wang D, Schultz CJ, Jursinic PA, et al. Initial experience of FDG-PET/CT guided IMRT of head and neck carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:143–151
  32. Popple RA, Ove R, Shen S. Tumour control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 2002;54:921–927
  33. Madani I, Duthoy W, Derrie C, et al. Positron emission tomography guided focal dose escalation using intensity modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68:126–135
  34. Van der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by FDG-PET-CT planning in patients with clinical CT stage N2/N3 M0 non small cell lung cancer (NSCLC): a modeling study. Int J Radiat Oncol Biol Phys. 2005;61:648–654
  35. Soret M, Bacharacj SL, Buvat I, et al. Partial volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–945
  36. Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: voxel size matters. Acta Oncol. 2008;47:1201–1210
  37. Reader AJ. The promise of a new PET image reconstruction. Phys Med. 2008;24:49–56
  38. Christian N, Lee JA, Bol A, et al. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol. 2009;91:101–106
  39. Nehmeh SA, Lee NY, Schröder H, et al. Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235–242
  40. Sovik A, Malinen E, Skogmo HK, Bentzen SM, Bruland OS, Olsen DR. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys. 2007;68:1496–1504
  41. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys. 2007;68:291–300
  42. Søvik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys. 2009;73:650–658
  43. Vanderstraeten B, Reynaert N, Paelinck L, et al. Accuracy of patient dose calculation for lung IMRT: A comparison of Monte Carlo, convolution/superposition, and pencil beam computations. Med Phys. 2006;33:3149–3158
  44. Flynn RT, Bowen SR, Bentzen SM, Rockwell Mackie T, Jeraj R. Intensity-modulated X-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol. 2008;53:4153–4167
  45. Thorwarth D, Soukup M, Alber M. Dose painting with IMPT, helical tomotherapy and IMXT: a dosimetric comparison. Radiother Oncol. 2008;86:30–34
  46. Bowen SR, Flynn RT, Bentzen SM, Jeraj R. On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Phys Med Biol. 2009;54:1483–1501
  47. Vanderstraeten B, De Gersem W, Duthoy W, De Neve W, Thierens H. Implementation of biologically conformal radiation therapy (BCRT) in an algorithmic segmentation-based inverse planning approach. Phys Med Biol. 2006;51:N277–N286
  48. Rickhey M, Koelbl O, Eilles C, Bogner L. A biologically adapted dose-escalation approach, demonstrated for 18F-FET PET in brain tumours. Strahlenther Onkol. 2008;184:536–542
  49. Sattler B, Lee JA, Lonsdale M, Coche E. PET/CT (and CT) instrumentation, image reconstruction and data transfer for radiotherapy planning. Radiother Oncol. 2010;96:288–297
  50. Lee JA. Segmentation of positron emission topography images: Some recommendations for target delineation in radiation oncology. Radiother Oncol. 2010;96:302–307
  51. Haubner R. PET radiopharmaceuticals in radiation treatment planning – Synthesis and biological characteristics. Radiother Oncol. 2010;96:280–287
  52. Wang W, Georgi JC, Nehmeh SA, et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol. 2009;54:3083–3099
  53. Dirix P, Vandevaceye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with 18F-FDG, 18F-fluoromisonidazole, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med. 2009;50:1020–1027
  54. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol. 2005;50:2209–2224
  55. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging. 2005;32:1284–1291
  56. Rajendran JG, Schwartz DL, O’Sullivan J, et al. Tumor hypoxia imaging with [18-F] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–5441
  57. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-fluoromisonidazole PET in non-small cell lung cancer and head and neck cancer. J Nucl Med. 2005;46:253–260
  58. Troost EG, Vogel WV, Merkx MA, et al. 18F-FLT PET do not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726–735
  59. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med. 2010;51:866–874
  60. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck cancer based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys. 2007;68:515–521
  61. Malandrain G. Guidelines for the use of PET/CT in radiotherapy treatment planning. Image registration. Radiother Oncol 2010; in press.
  62. Hwang AB, Bacharach SL, Yom SS, et al. Can positron emission tomography (PET) or PET/computed tomography (CT) acquired in a nontreatment position be accurately registered to a head-and-neck radiotherapy planning CT?. Int J Radiat Oncol Biol Phys. 2009;73:578–584
  63. Aerts HJWL, van Baardwijk AAW, Petit SF, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan. Radiother Oncol. 2009;91:386–392
  64. Soto DE, Kessler ML, Piert M, Eisbruch A. Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol. 2008;89:13–18
  65. Brouwer J, de Bree R, Comans EFI, et al. Improved detection of recurrent laryngeal tumor after radiotherapy using 18FDG-PET as initial method. Radiother Oncol. 2008;87:217–220
  66. Gillham C, Zips D, Pönisch F, et al. Additional PET/CT in week 5–6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiother Oncol. 2008;88:335–341

PII: S0167-8140(10)00403-2

doi: 10.1016/j.radonc.2010.07.012

Radiotherapy & Oncology
Volume 96, Issue 3 , Pages 317-324 , September 2010

Article Tools

* Image Usage & Resolution